

Comparison of Treatment Outcomes of New Smear-Positive Pulmonary Tuberculosis Patients by HIV and Antiretroviral Status in a TB/HIV Clinic, Malawi

Hannock Tweya^{1,2*}, Caryl Feldacker^{2,3}, Sam Phiri², Anne Ben-Smith⁴, Lukas Fenner⁵, Andreas Jahn^{3,6}, Mike Kalulu², Ralf Weigel^{2,7}, Chancy Kamba⁸, Rabbecca Banda², Matthias Egger⁵, Olivia Keiser⁵

1 The International Union Against Tuberculosis and Lung Disease, Paris, France, **2** Lighthouse Trust, Lilongwe, Malawi, **3** International Training and Education Center for Health, University of Washington, Seattle, Washington, United States of America, **4** Department of Biomedical Informatics, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America, **5** Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland, **6** Central Monitoring and Evaluation Division/Department for HIV and AIDS, Ministry of Health, Lilongwe, Malawi, **7** Disease Control Strategy group, Liverpool School of Tropical Medicine, Liverpool, United Kingdom, **8** Ministry of Health, Lilongwe District Health Office, Lilongwe, Malawi

Abstract

Background: Smear-positive pulmonary TB is the most infectious form of TB. Previous studies on the effect of HIV and antiretroviral therapy on TB treatment outcomes among these highly infectious patients demonstrated conflicting results, reducing understanding of important issues.

Methods: All adult smear-positive pulmonary TB patients diagnosed between 2008 and 2010 in Malawi's largest public, integrated TB/HIV clinic were included in the study to assess treatment outcomes by HIV and antiretroviral therapy status using logistic regression.

Results: Of 2,361 new smear-positive pulmonary TB patients, 86% had successful treatment outcome (were cured or completed treatment), 5% died, 6% were lost to follow-up, 1% failed treatment, and 2% transferred-out. Overall HIV prevalence was 56%. After adjusting for gender, age and TB registration year, treatment success was higher among HIV-negative than HIV-positive patients (adjusted odds ratio 1.49; 95% CI: 1.14–1.94). Of 1,275 HIV-infected pulmonary TB patients, 492 (38%) received antiretroviral therapy during the study. Pulmonary TB patients on antiretroviral therapy were more likely to have successful treatment outcomes than those not on ART (adjusted odds ratio : 1.83; 95% CI: 1.29–2.60).

Conclusion: HIV co-infection was associated with poor TB treatment outcomes. Despite high HIV prevalence and the integrated TB/HIV setting, only a minority of patients started antiretroviral therapy. Intensified patient education and provider training on the benefits of antiretroviral therapy could increase antiretroviral therapy uptake and improve TB treatment success among these most infectious patients.

Citation: Tweya H, Feldacker C, Phiri S, Ben-Smith A, Fenner L, et al. (2013) Comparison of Treatment Outcomes of New Smear-Positive Pulmonary Tuberculosis Patients by HIV and Antiretroviral Status in a TB/HIV Clinic, Malawi. PLoS ONE 8(2): e56248. doi:10.1371/journal.pone.0056248

Editor: Wenzhe Ho, Temple University School of Medicine, United States of America

Received: October 9, 2012; **Accepted:** January 7, 2013; **Published:** February 15, 2013

Copyright: © 2013 Tweya et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: Hannock Tweya is supported as an Operational Research Fellow by the International Union Against Tuberculosis and Lung Disease, Paris, France. Caryl Feldacker was supported with funding from Cooperative Agreement U91HA06801 from the US Department of Health and Human Services, Health Resources and Services Administration (HRSA) and Olivia Keiser is supported by a PROSPER grant from the Swiss National Science Foundation. This publication was made possible by Grant Number U01AI069924 from the NIH (NIAID, NICHD, NCI) and 3 U01 AI069924-05S1 from PEPFAR. (PI: Egger and Davies). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: h_tweya@lighthouse.org.mw

Introduction

Approximately one third of the world's population is infected with tuberculosis (TB) bacilli and at risk of developing active TB [1]. In 2010, there were an estimated 12 million TB cases, including 8.8 million incident cases [1]. Smear-positive pulmonary TB (PTB) constitutes 34% of new TB cases [2] and is most likely a source of TB transmission in the community. In sub-Saharan Africa, high HIV prevalence increases the risk of developing TB. An estimated 40% of African TB cases were HIV co-infected in 2010, and 24% of 1.45 million TB deaths globally were among HIV-infected people [1].

Due to the high HIV prevalence among TB patients, WHO recommends the Three I's: intensified TB screening among HIV-infected individuals, provision of isoniazid preventive therapy (IPT), and infection control [3]. Adoption of the comprehensive service package, in particular provision of IPT, by the Malawi national HIV programme was a challenge due to its implementation requirements. However, Malawi's national HIV programme started providing IPT among pre-ART patients in 2011 [4].

Treatment success in TB patients is a major challenge in TB programmes. TB treatment outcomes (cured, treatment complet-

ed, died, treatment failure, lost to follow-up (LTFU) or transferred-out) are known to be influenced by a number of factors including HIV co-infection, but the evidence on what factors are most influential appears inconclusive. While some studies found lower TB cure rates among TB/HIV patients [5,6], other studies reported comparable TB cure rates among those TB/HIV co-infected to those infected only with TB [7,8]. Most of these studies were limited by a number of factors. First, they were conducted largely prior to the widespread use of ART [5–6], which improves survival [9]. Second, other studies showed reduction in mortality among HIV-infected TB patients who accessed antiretroviral therapy (ART) [10–12]; however, these studies focused on ART and not TB outcomes, reducing their application to strengthen TB programmes.

Understanding TB treatment outcomes of new smear-positive PTB cases may provide an indication of the effectiveness of national TB programmes. We, therefore conducted a study to explore TB treatment outcomes of new smear-positive adult PTB cases among those who accessed treatment at Malawi's largest public TB registration site, Martin Preuss Centre (MPC), in the capital, Lilongwe. MPC integrates TB and ART services.

Therefore, we were able to stratify by HIV and ART status to understand better the role of these critical factors.

Methods

Setting

The study was conducted at the Martin Preuss Centre (MPC), an integrated TB/HIV clinic run by the Malawi Ministry of Health's Lilongwe District Health Office in partnership with the Lighthouse Trust. MPC, described in detail previously [13], has three units: HIV testing and counseling, ART, and TB which includes sputum submission. "Opt-out" HIV testing and counseling services are also provided within the TB unit; over 95% know their HIV status before starting TB treatment. MPC registers approximately 3,200 TB patients annually. Diagnosis of TB is based on clinical examination, sputum smear microscopy, chest radiography and other investigations as appropriate for extrapulmonary disease. Once diagnosed with TB, patients are recorded in the national TB register by the district TB officer. The Malawi National TB control (NTP) program classifies new smear-positive PTB patients as, "patients with positive smear result who have never taken anti-tuberculosis drugs for more than

Table 1. Patient characteristics by TB treatment outcomes for new smear-positive TB patients at Martin Preuss Centre between January 2008 and December 2010.

Characteristics	Total (Column: #, %)		TB treatment outcome							P-value			
			Success [‡]	Died	LTFU [*]	Transfer out	failure						
Total	2,361		2,041	86%	110	5%	146	6%	50	2%	14	1%	
Sex													0.010
Male	1,460	62%	1,238	85%	73	5%	103	7%	39	3%	7	1%	
Female	901	38%	803	89%	37	4%	43	5%	11	1%	7	1%	
Age													0.030
15–24	481	20%	415	86%	17	4%	37	8%	8	2%	4	<1%	
25–34	1,023	43%	893	87%	35	3%	61	6%	28	3%	6	1%	
35–44	525	22%	458	87%	27	5%	30	6%	8	2%	2	<1%	
45–54	186	8%	155	83%	18	10%	9	5%	3	2%	1	1%	
≥55	146	6%	120	82%	13	9%	9	6%	3	2%	1	1%	
Treatment site[§]													0.272
MPC	943	40%	801	85%	22	2%	87	9%	26	3%	7	1%	
Other	1,416	60%	1,238	87%	88	6%	59	4%	24	2%	7	<1%	
TB registration year													<0.001
2008	841	36%	753	90%	43	5%	19	2%	16	2%	10	2%	
2009	869	37%	729	84%	39	4%	87	10%	12	1%	2	<1%	
2010	651	28%	559	86%	28	4%	40	6%	22	3%	2	<1%	
HIV status[‡]													0.017
HIV positive	1,275	56%	1,086	85%	72	6%	84	7%	28	2%	5	<1%	
HIV negative	989	44%	875	88%	31	3%	56	6%	18	2%	9	1%	
ART status[‡]													0.014
On ART	492	39%	437	89%	16	3%	28	6%	8	2%	3	1%	
Not on ART	783	61%	649	83%	56	7%	56	7%	20	3%	2	<1%	

[‡]Success = cured or treatment complete,

[‡]Included HIV positive only,

[‡]97 TB cases had missing HIV status,

[§]2 TB cases had missing treatment site.

^{*}LTFU = lost to follow-up.

doi:10.1371/journal.pone.0056248.t001

Table 2. Baseline characteristics and TB treatment outcomes of new smear-positive adult PTB patients by HIV status at Martin Preuss Centre between January 2008 and December 2010.

Characteristics	Total [n (%)]		HIV Positive [n (%)]		HIV Negative [n (%)]		P-value ^F
Overall	2,264		1,275	56%	989	44%	
Gender							0.004
Male	1,400	62%	755	59%	645	65%	
Female	864	38%	520	41%	344	35%	
Age at TB registration							<0.001
15–24	460	20%	169	13%	291	29%	
25–34	985	44%	619	49%	366	37%	
35–44	505	22%	350	27%	155	16%	
45–54	173	8%	100	8%	73	7%	
≥55	141	6%	37	3%	104	10%	
TB Treatment site							0.029
MPC	912	40%	533	42%	379	38%	
Other	1,352	60%	742	58%	610	62%	
TB registration year							0.070
2008	791	35%	421	33%	370	37%	
2009	843	37%	496	39%	347	35%	
2010	630	28%	358	28%	272	28%	
TB Treatment outcome^Y							0.017
Treatment success	1,960	87%	1085	85%	875	88%	
Cured	1,601	82%	869	80%	732	84%	
Completed	359	18%	216	20%	143	16%	
Lost to follow-up	140	6%	84	7%	56	6%	
Treatment failure	14	<1%	5	<1%	9	1%	
Died	103	5%	72	6%	31	3%	
Transfer-out	46	2%	28	2%	18	2%	

^Y110 TB cases had unknown Tb treatment outcome and treatment success = cured/completed.

^Fchi-square test for difference.

doi:10.1371/journal.pone.0056248.t002

one month” [14]. All new adult TB cases are treated with the standard WHO regimen I, consisting of two months of daily rifampicin (R), Isoniazid (H), pyrazinamide (Z) and ethambutol (E), followed by four months of RHE.

Approximately 50% of patients initiate and continue TB treatment at MPC; the rest initiate at MPC but choose to continue their treatment at one of 18 peripheral health facilities in accordance with NTP decentralization efforts. Treatment outcomes of all patients who initiate at MPC regardless of where they continue treatment are recorded and updated using TB treatment cards in the MPC central TB register. The Malawi NTP defines TB treatment outcomes as: 1) cured: a patient who was smear-positive at diagnosis and has smear-negative results at, or one month prior to, completion of TB treatment; 2) treatment completed: a patient who completed treatment (i.e. took a full course of treatment) but for whom smear results are not available on, or one month prior, to the completion of TB treatment; 3) failure: a patient who remains, or returns, smear-positive at five months or more during TB treatment; 4) death: a patient who died from any cause during TB treatment; 5) lost to follow-up: a patient who stopped TB treatment for more than two months; 6) transferred-out: a patient who (presumably) completed TB treatment at another TB registration site. Deaths are ascertained mainly through active follow-up.

MPC also provides ART to HIV-infected individuals. All TB patients diagnosed with HIV were eligible for ART and expected to initiate ART within two months of TB registration. ART was co-administered with TB treatment and available for all patients regardless of where they chose to continue TB treatment.

Study Design and Population

We included all new smear-positive adult PTB patients (≥15 years) who registered and initiated TB treatment at MPC between January 2008 and December 2010. Patients who completed TB treatment at MPC or a peripheral site were included.

Data Collection and Data Analysis

Variables for all new smear-positive PTB cases were collected from routine programme data including TB registers and patient treatment cards. Variables included TB registration number, registration date, age, gender, HIV status, ART status and TB treatment outcome. Data were entered and cleaned in a MS Access database and analyzed in STATA 10.0. We used chi-square tests to compare patient characteristics and all TB treatment outcomes stratified by HIV and ART status. TB cases with missing treatment outcomes were excluded from further analysis. The effects of HIV and ART status on TB treatment outcome were examined using logistic regression models. TB

Table 3. Factors associated with TB treatment success among new smear-positive TB patients at Martin Preuss Centre between January 2008 and December 2010 (N = 2,264)[‡].

Characteristics	Total		Unadjusted Odds Ratio (95% CI)	P-value*	Adjusted Odds Ratio (95% CI) [‡]	P-value*
	N	%				
HIV Status				0.019		0.003
HIV positive	1,275	56%	1.00		1.00	
HIV negative	989	44%	1.34 (1.05–1.72)		1.49 (1.14–1.94)	
Gender				0.005		0.002
Male	1,400	62%	1.00		1.00	
Female	864	38%	1.45 (1.12–1.87)		1.52 (1.17–1.99)	
Age category				0.323		0.065
15–24	460	20%	0.90 (0.65–1.25)		0.76 (0.54–1.06)	
25–34	985	44%	1.00		1.00	
35–44	505	22%	0.98 (0.71–1.36)		1.07 (0.77–1.48)	
45–54	173	8%	0.71 (0.46–1.10)		0.70 (0.45–1.10)	
≥55	141	6%	0.66(0.41–1.06)		0.57 (0.35–0.93)	
TB Registration year				<0.001		<0.001
2008	791	35%	1.80 (1.34–2.43)		1.79 (1.33–2.41)	
2009	843	37%	1.00		1.00	
2010	630	28%	1.23 (0.92–1.65)		1.22 (0.91–1.63)	
TB Treatment site				0.147		
MPC	912	40%	1.20 (0.94–1.53)		-	
Other	1,352	60%	1.00			

*P-value for likelihood ratio test.

[‡]Adjusted for sex, age, HIV status and TB registration year.[‡]Treatment success = cured/completed treatment.

doi:10.1371/journal.pone.0056248.t003

treatment outcome was categorised as treatment success (“cured” or “treatment completed”) versus all other treatment outcomes. The final multivariable model was determined using forward selection, including explanatory variables with a two-sided p-value of ≤ 0.05 . Age group, in 10-year bands, and gender were included a priori in the final multivariable logistic regression model. Linear trends for treatment success were explored using chi-square tests. Statistical significance for all analyses was set at the $p \leq 0.05$ level and 95% confidence intervals (CI) were calculated throughout.

Ethical Considerations

The study was approved by the Malawi National Health Science Research Committee and the Ethics Advisory Group of the International Union Against Tuberculosis and Lung Disease in Paris, France. The data for the study did not include any personal identifiers. The ethics committees waived the need for patient consent because the study used routine programmatic data that did not include any personal identifiers.

Results

Study Population

Between January 2008 and December 2010, 2,478 new, smear-positive, adult PTB cases were registered at MPC. Men comprised 62% (1,530) of all patients. The median age was 31 years (Interquartile range (IQR) 26–38 years). There were no age differences across years of TB registration. A total of 117 (5%) patients had unknown TB treatment outcome and were excluded in further analyses. Of the remaining 2,361, 86% had treatment

success (1664 were cured and 376 completed treatment), 5% died, 6% were LTFU, 2% transferred-out and 1% had treatment failure (**Table 1**). Treatment success decreased from 90% in 2008 to 84% and 86% in 2009 and 2010, respectively (test for trend $p = 0.013$). The proportions of LTFU were higher in 2009 (10%) and 2010 (6%) compared to 2008 (2%).

Comparison of Smear-positive PTB Patient Treatment Outcomes by HIV Status

Most patients (2,264, 96%) knew their HIV status. HIV prevalence was 56%: 60% in women and 54% in men. HIV-negative patients had slightly better TB outcomes compared to HIV-positive patients. Of HIV-negative patients, 88% had successful treatment outcomes compared to 85% of HIV-positive patients. More HIV-infected TB patients died (6%) compared to HIV-negative patients (3%) ($p = 0.034$) (**Table 2**). In univariable logistic regression analyses, being female (OR = 1.45, 95% CI 1.12–1.87, $p = 0.005$) and being HIV-negative (OR 1.34, 95% CI 1.05–1.72, $p = 0.019$) were both associated with successful TB treatment outcome while age ($p = 0.323$) and treatment site ($p = 0.147$) were not associated (**Table 3**). Compared to 2009, treatment success was higher in 2008 (OR = 1.80 95% CI 1.34–2.43) but similar to 2010 (OR = 1.23 95% CI 0.92–1.65). After adjusting for age, gender and TB registration year, treatment success among HIV-negative PTB cases increased compared to HIV-infected peers (adjusted OR = 1.49, 95% CI 1.14–1.94).

Table 4. Factors associated with TB treatment success among new smear-positive TB/HIV co-infected patients at Martin Preuss Centre between January 2008 and December 2010 [‡] (N = 1,275).

Characteristics	Total		Unadjusted Odds Ratio (95% CI)	P-value*	Adjusted Odds Ratio (95% CI) [‡]	P-value*
	N	%				
ART Status				0.005		0.001
On ART	492	39%	1.61 (1.15–2.25)		1.83 (1.29–2.60)	
Not on ART	783	61%	1.00		1.00	
Gender				0.031		0.032
Female	520	41%	1.43 (1.03–1.97)		1.44 (1.03–2.01)	
Male	755	59%	1.00		1.00	
Age at TB registration				0.515		0.373
15–24	169	13%	0.76 (0.48–1.19)		0.70 (0.44–1.12)	
25–34	619	49%	1.00		1.00	
35–44	350	27%	0.98 (0.67–1.43)		1.06 (0.72–1.55)	
45–54	200	8%	0.70 (0.40–1.21)		0.73 (0.42–1.28)	
≥55	37	3%	1.35 (0.47–3.90)		1.43 (0.49–4.17)	
TB Registration year				0.004		<0.001
2008	421	33%	1.90 (1.30–2.79)		2.17 (1.46–3.22)	
2009	496	39%	1.00		1.00	
2010	358	28%	1.31 (0.91–1.90)		1.22 (0.84–1.78)	

*P-value for likelihood ratio test,

[‡]Adjusted for sex, age, ART status and TB registration year,[‡]Treatment success = cured/completed treatment.

doi:10.1371/journal.pone.0056248.t004

Comparison of Smear-positive PTB Patient Treatment Outcomes by ART Status

Of the 1,275 HIV-infected new smear-positive PTB cases, 492 (38%) received ART during the study period. There were no significant differences in terms of gender and age distributions between those on ART and not. However, the proportion of patients on ART increased from 17% in 2008 to almost 40% in 2010 ($p < 0.001$). Patients on ART had more successful treatment outcomes (89%) compared to those not on ART (83%) ($p = 0.014$). TB patients who were on ART were less likely to die than those not on ART (adjusted OR = 0.46 95% CI 0.26–0.83). In multivariable logistic regression, treatment success was higher among smear-positive PTB patients on ART than among those not on ART (adjusted OR = 1.83, 95% CI: 1.29–2.60) (**Table 4**).

Discussion

This is one of the largest studies to examine the effects of HIV and ART status on TB treatment outcomes among new smear-positive PTB patients in sub-Saharan Africa. In our study, overall treatment success was 86%, indicating an overall positive programme outcome. Fifty six percent of smear-positive PTB patients were HIV co-infected and HIV co-infection was associated with a slightly poorer TB treatment outcome, even after adjusting for gender, age and year of TB registration. Only 38% of the TB/HIV new smear-positive co-infected patients were on ART. Those on ART had successful TB treatment outcomes compared to those not on ART.

Similar to other studies [15,16], we found a high proportion of smear-positive PTB among individuals aged 15–44 years; the same ages are at highest risk of HIV in Malawi [17]. However, HIV prevalence among our smear-positive PTB patients (56%) was

lower than the national HIV prevalence of 68% among all TB forms [18]. This finding is likely because the national estimation of HIV prevalence in TB-infected individuals includes those with smear-negative PTB, which is quite common among HIV-infected individuals [19].

As expected, both HIV and ART status influenced TB treatment outcomes. In general, HIV-infected individuals were less likely to have successful treatment outcomes and were twice as likely to die as compared to HIV-negative individuals. Among HIV-infected smear-positive PTB adults, those on ART had slightly higher likelihood of successful treatment outcomes compared to those not on ART. ART enhances the immune response among HIV-infected TB patients, and this consequently leads to improved survival [20]. More dramatically, we also found a 50% reduction in mortality among TB patients on ART compared to those not on ART, an indication of the positive effect of TB/ART co-infection treatment, which echoes similar findings from previous studies [9,21].

Despite the well-known benefit of ART and the integrated TB/HIV care model at MPC, only 38% of HIV-infected new smear-positive individuals received ART during TB treatment. The low ART uptake is likely due to several factors. First, some patients might be reluctant to take ART and TB drugs simultaneously due to concerns about pill burden and drug interactions. Second, the national ART guidelines recommend a guardian before ART initiation; the absence of a guardian may delay or discourage ART uptake among TB patients. Lastly, smear-positive PTB patients are expected to be reviewed by TB clinical officers – a cadre of mid-level healthcare professionals trained in both TB and ART management. However, in practice, health surveillance assistants (the lowest level of healthcare professionals) who are not trained in ART provision often conduct TB reviews for HIV-infected

individuals, sometimes overlooking the need for ART initiation [13]. Currently shifting management of smear-positive PTB patients from health surveillance assistants to TB clinical officers is under discussion within the Malawi NTP with the aim of improving routine programme management.

Our results should be viewed in light of the following limitations. TB treatment outcomes were not available for 5% of eligible patients and their exclusion might have introduced bias. However, there were no significant differences in terms of age, gender and HIV status between patients with and without TB treatment outcomes. Second, we used only routine programme data; these do not include information such as viral load and CD4 cell count which may have significant effects on patients' TB outcomes. Third, since 165 (34%) of HIV-infected individuals on ART did not have a recorded ART start date, we could not explore the effect of duration on ART or timing of ART uptake on TB outcomes. Previous studies found decreased treatment success for sequential ART initiation [9]. Despite these limitations, the study findings are useful to inform policy and programmes that aim to improve management of new smear-positive TB/HIV patients in Malawi and other comparable settings.

The results of this study suggest several changes that would likely improve TB outcomes and reduce the duration of infectiousness especially among TB/HIV co-infected patients in an integrated TB/HIV clinic setting. First, although our study

found satisfactory treatment outcomes for smear-positive PTB patients, this rate decreased from 90% in 2008 to 84% in 2009 and to 86% in 2010, possibly due to changing LTFU rates. In an effort to address LTFU, the Malawi HIV programme recommends active tracing of TB/HIV patients in facilities providing HIV services, a step that MPC will consider. Second, appropriate and intensified sensitization on the benefits of ART for both patients and care providers might increase ART uptake. Lastly, improved monitoring and evaluation of TB/HIV co-infected patient care, especially as provided by health surveillance assistants, would better identify and address obstacles in ART initiation during follow-up visits.

Acknowledgments

The authors would like to thank all the TB staff at Martin Preuss Center who collected data. We thank numerous donors supporting the Lighthouse and the Malawi national ART program.

Author Contributions

Conceived and designed the experiments: HT CF CK RB MK SP RW OK. Performed the experiments: HT CF CK RB MK SP RW OK. Analyzed the data: HT CF AB OK LF AJ ME. Contributed reagents/materials/analysis tools: HT CF AB OK LF AJ ME. Wrote the paper: HT CF CK RB MK SP RW OK AB LF AJ ME.

References

1. WHO (2011) Global Tuberculosis Control Report. Geneva, Switzerland: World Health Organisation.
2. WHO (2010) Global Tuberculosis Control Report Geneva, Switzerland: World Health Organisation.
3. WHO (2008) WHO Three I's Meeting Intensified Case Finding (ICF), Isoniazid Preventive Therapy (IPT) and TB Infection Control (IC) for people living with HIV, Report of a Joint World Health Organization HIV/AIDS and TB Department Meeting. Geneva, Switzerland.
4. MoH (2011) Clinical Management of HIV in Children and Adults; Integrated Guidelines for Providing HIV Services Lilongwe: Malawi Ministry Of Health.
5. Banerjee A, Moyo S, Salaniponi F, Harries A (1997) HIV testing and tuberculosis treatment outcome in a rural district in Malawi. *Trans R Soc Trop Med Hyg* 91: 707–708.
6. Sume GE, Hoshen M, Bitá G, Kabore S, Nzima VN (2009) Treatment outcome of TB/HIV positive and negative smear positive pulmonary tuberculosis patients treated using daily self-administered therapy in a Cameroonian district hospital. *East Afr Med J* 86: 469–475.
7. Van den Broek J, Mfinanga S, Moshiri C, O'Brien R, Mugomela A, et al. (1998) Impact of human immunodeficiency virus infection on the outcome of treatment and survival of tuberculosis patients in Mwanza, Tanzania. *Int J Tuberc Lung Dis* 2: 547–552.
8. El-Sony AI, Khamis AH, Enarson DA, Baraka O, Mustafa SA, et al. (2002) Treatment results of DOTS in 1797 Sudanese tuberculosis patients with or without HIV co-infection. *Int J Tuberc Lung Dis* 6: 1058–1066.
9. Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, et al. (2010) Timing of initiation of antiretroviral drugs during tuberculosis therapy. *N Engl J Med* 362: 697–706.
10. Dhedda K, Lampe FC, Johnson MA, Lipman MC (2004) Outcome of HIV-associated tuberculosis in the era of highly active antiretroviral therapy. *J Infect Dis* 190: 1670–1676.
11. Sanguanwongse N, Cain KP, Suriya P, Nateniyom S, Yamada N, et al. (2008) Antiretroviral therapy for HIV-infected tuberculosis patients saves lives but needs to be used more frequently in Thailand. *J Acquir Immune Defic Syndr* 48: 181–189.
12. Manosuthi W, Chottanapand S, Thongyen S, Chaovavanich A, Sungkanuparph S (2006) Survival rate and risk factors of mortality among HIV/tuberculosis-coinfected patients with and without antiretroviral therapy. *J Acquir Immune Defic Syndr* 43: 42–46.
13. Phiri S, Khan PY, Grant AD, Gareta D, Tweya H, et al. (2011) Integrated tuberculosis and HIV care in a resource-limited setting: experience from the Martin Preuss centre, Malawi. *Trop Med Int Health*.
14. Malawi Ministry of Health (2007). Malawi National Tuberculosis Control Programme Manual.
15. Muvunyi CM, Masaisa F, Bayingana A, Musemakweri C, Mutesa L, et al. (2010) Prevalence and diagnostic aspects of sputum smear positive tuberculosis cases at a tertiary care institution in Rwanda. *Afr J Microbiol Res*, 4: 88–91 4: 88–91.
16. Holmes CB, Hausler H, Nunn P (1998) A review of sex differences in the epidemiology of tuberculosis. *Int J Tuberc Lung Dis* 2: 96–104.
17. UNAIDS website. Available: http://data.unaids.org/Publications/Fact-Sheets01/malawi_en.pdf. Accessed on 2011 September 15.
18. USAID website. Available: http://transition.usaid.gov/our_work/global_health/id/tuberculosis/countries/africa/malawi.pdf. Accessed on 2012 March 20.
19. WHO (2009) Global Tuberculosis Control - Epidemiology, Strategy, Financing. Geneva, Switzerland: World Health Organisation.
20. Oguntibeju O (2012) Quality of life of people living with HIV and AIDS and antiretroviral therapy. *HIV AIDS*. 2012; 4: 117–124.
21. Velasco M, Castilla V, Sanz J, Gaspar G, Condes E, et al. (2009) Effect of simultaneous use of highly active antiretroviral therapy on survival of HIV patients with tuberculosis. *J Acquir Immune Defic Syndr* 50: 148–152.